Pharmacyclics (4/5/13) â Ibrutinib â Expanding the Potential – Pancreatic Cancer, Combination Therapies and Recovery of Functional Immunity â Reiterate BUY UNDER 80 and TARGET PRICE OF 115. The AACR meeting begins this weekend in Washington, D.C. An overwhelming number of studies by every oncology company, both preclinical and human trials, are due to be[…]